Elle Investments | TalkMarkets | Page 1

Elle Investments

Family Office
Contributor's Links: Elle Investments
Elle Investments is a small family office. At the single investment level, we look for asymmetric opportunities generally created by a disconnect between value (fundamentals or upside opportunity) and market sentiment. Long-term portfolio risk is managed through a “quantamental ...more
Following: 5 Followers: 1192

Articles

Latest Posts
1 to 13 of 13 Posts
Research Report: Vera Bradley (VRA)
Thursday, July 16, 2020 8:07 PM EDT
A contrarian bet in the retail sector. The stock has not recovered yet from the COVID-19 sell-off, the balance sheet is adequate, and they saw positive organic growth the prior year.
In this article: VRA
Read
Research Report: Townsquare Media (TSQ)
Monday, June 22, 2020 12:00 PM EDT
TSQ has been overly punished from its high debt load and past association with a larger Live Events footprint. But both risks are overstated.
In this article: TSQ
Read
Research Report: AcelRx Pharmaceuticals (ACRX)
Tuesday, May 26, 2020 1:12 PM EDT
Sales of sublingual sufentanil tablet Dsuvia have been slow out of the gate, but we remain very bullish on the long-term prospects.
In this article: ACRX
Read
Research Report: ObsEva (OBSV)
Tuesday, May 5, 2020 1:16 PM EDT
The company will need more financing if they don't secure a commercial partner, but phase 3 results demonstrate that linzagolix will be another beneficial option for physicians treating uterine fibroids and endometriosis.
In this article: OBSV
Read
Research Report: Vericel Corporation
Wednesday, April 1, 2020 12:00 PM EDT
Shares sold off hard from the COVID-19 panic. But they have plenty of cash, no debt, and we are confident that strong MACI sales growth will resume once elective surgeries do.
In this article: VCEL
Read
Research Report: Tailored Brands (TLRD)
Monday, June 17, 2019 4:23 PM EDT
TLRD is battling two very disruptive trends in men’s fashion. While it’s too early to tell if the changes they are making can stabilize the negative trend in comps, any signs of improvement will signal that they are not just another dying retailer.
In this article: TLRD
Read
Research Report: ODP
Wednesday, May 29, 2019 9:00 PM EDT
After climbing to above $3.50/share in early April, ODP has sold off almost 50%, driven by the lower than expected operating performance at the CompuCom division.
In this article: ODP
Read
Research Report: Townsquare Media
Friday, May 24, 2019 6:16 PM EDT
In 2018, TSQ's continuing operations generated $44M of free cash flow to equity (FCFE). Based on management’s 2019 adjusted EBITDA guidance, 2019 should see another $40M+ of FCFE. The forward PE and the 5.5% dividend yield make this a strong buy.
In this article: TSQ
Read
Research Report: PBYI
Friday, May 24, 2019 1:41 PM EDT
The lowered 2019 Nerlynx net sales guidance after 1Q19 results puts previous peak sales estimates of $1B+ in doubt. However, given the large sell-off, even with much lower peak sales estimates in the $500M+ range, there is still a lot of upside.
In this article: PBYI
Read
Research Report: XIN
Sunday, May 12, 2019 9:47 PM EDT
XIN is a Chinese real estate company trading at a depressed valuation (common for Chinese companies). But the projects outside of China, the investment by global firm TPG, and the 29 consecutive dividends (currently at 9%) significantly de-risk this.
In this article: XIN
Read
Research Report: MDR
Wednesday, May 8, 2019 1:12 AM EDT
We continue to remain very bullish on MDR even after the reaction to 1Q19 earnings, and think that the forward P/E of 3.6x (based on 2020 and beyond EPS) indicates that it has been too overly-punished. This is a strong buy.
In this article: MDR
Read
Research Report: Akebia Therapeutics, Inc.
Saturday, April 20, 2019 3:11 PM EDT
As of 4Q18, AKBA had cash of $322M. Additionally, AKBA is eligible to receive over $150M in development and regulatory milestones from its collaboration partners.
In this article: AKBA
Read
Puma Biotechnology: A Favorable Risk/Reward Bet
Thursday, April 11, 2019 2:31 PM EDT
PBYI dropped about 8% when the EU/Africa licensing deal with Pierre Fabre was announced for potential blockbuster candidate Nerlynx, which is currently approved in the US and EU for HER2+ breast cancer treatment (post-Herceptin).
In this article: PBYI
Read
1 to 13 of 13 Posts